Skip to content
DataLookout
Menu

NATiV3NCT04849728

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 44 versions: 44 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 40 words
    • Primary completion date changed from estimate of Sep 30, 2027 to Sep 29, 2026
    • Study description expanded, about 11 words
    • Site details revised at 44 of 459 sites
  2. Minor Site details revised at 46 of 459 sitesv43
  3. Minor Primary and study completion pushed from Jun 30, 2027 to Sep 30, 2027
    • Trial sites expanded: 434 → 459 locations
    v42
  4. Notable Primary and study completion pushed from Dec 30, 2026 to Jun 30, 2027
    • Trial sites expanded: 428 → 434 locations
    v41
  5. Notable Primary and study completion dates pushed to Dec 30, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 494 to 428
    v40
Show 38 earlier versionsHide 38 earlier versions
  1. Minor Site details revised at 1 of 494 sitesv39
  2. Minor Site details revised at 1 of 494 sitesv38
  3. Minor Site details revised at 2 of 494 sitesv37
  4. Minor Site details revised at 3 of 494 sitesv36
  5. Minor Study sites: 493 to 494v35
  6. Minor Site details revised at 4 of 493 sitesv34
  7. Minor Site details revised at 7 of 493 sitesv33
  8. Minor Study sites revised (493)v32
  9. Minor Site details revised at 4 of 493 sitesv31
  10. Minor Study sites: 491 to 493v30
  11. Minor Site details revised at 1 of 491 sitesv29
  12. Minor Site details revised at 1 of 491 sitesv28
  13. Minor Study sites: 486 to 491v27
  14. Minor Study sites: 407 to 486v26
  15. Minor Study sites: 397 to 407v25
  16. Minor Study sites: 395 to 397v24
  17. Minor Study sites: 394 to 395v23
  18. Minor Study sites: 391 to 394v22
  19. Minor Study sites: 385 to 391v21
  20. Minor Study sites: 382 to 385v20
  21. Minor Study sites: 383 to 382v19
  22. Minor Study sites: 378 to 383v18
  23. Minor Study sites: 354 to 378v17
  24. Notable Enrollment target: 2000 to 1000v16 Show 7 more changesShow less
    • Primary completion date: Feb 2024 to Sep 30, 2025
    • Eligibility criteria expanded, about 52 words
    • Primary endpoints revised (2)
    • Study sites: 353 to 354
    • Study completion date: Sep 2028 to Sep 30, 2026
    • Study description shortened, about 11 words
    • Study title expanded, about 4 words
  25. Minor Study sites: 337 to 353v15
  26. Minor Study sites: 291 to 337v14
  27. Minor Study sites: 255 to 291v13
  28. Minor Study sites: 223 to 255v12
  29. Minor Study sites: 183 to 223v11
  30. Minor Study sites: 148 to 183v10
  31. Minor Study sites: 88 to 148v9
  32. Minor Study sites: 65 to 88v8
  33. Minor Study sites: 51 to 65v7
  34. Minor Study sites: 27 to 51v6
  35. Minor Study sites: 14 to 27v5
  36. Minor Study sites: 13 to 14v4
  37. Notable Eligibility criteria shortened, about 1,045 wordsv3 Show 4 more changesShow less
    • Primary endpoints: 1 to 2
    • Study sites: 1 to 13
    • Start date changed from estimate of Aug 2021 to Aug 19, 2021
    • Interventions: Lanifibranor (Drug) to IVA337 (Drug), Placebo (Drug)
  38. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Jul 2021 to Aug 2021
    • Study title shortened, about 7 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Resolution of NASH and improvement of fibrosis
Timeframe: Part A: Date of randomisation until the date of biopsy at Week 72
Safety Analyses
Timeframe: 48 weeks after completion of DBPC period

Arms and interventions

Lanifibranor (IVA 337) (800 mg/day)Experimental

2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --\> once a day (quaque die, QD)

Lanifibranor (IVA 337) (1200 mg/day)Experimental

3 Lanifibranor tablets 400mg with food --\> once a day (quaque die, QD)

Matching placeboPlacebo comparator

3 Placebo to match tablets with food --\> once a day (quaque die, QD)

Drugs: IVA337, Placebo

Sites

459 sites in 24 countries

United States 194, China 71, France 27, Spain 19, Mexico 18, Germany 12, United Kingdom 12, Australia 11, Poland 11, Belgium 10, Italy 10, Israel 9, Canada 7, Argentina 6, Bulgaria 6, Netherlands 6, Portugal 6, South Africa 6, Brazil 5, Hungary 5, Chile 3, Puerto Rico 2, Ukraine 2, Czechia 1